Table 1.
Correlation between CBX7 expression in gastric cancer tissues and clinicopathological variables
| CBX7(+) | CBX7(−) | P value | |
|---|---|---|---|
| Lymph node metastases | |||
| Negative | 5 (23.8%) | 16 (76.2%) | 0.054 |
| Positive | 35 (47.3%) | 39 (52.7%) | |
| Depth of invasion | |||
| T1–3 | 16 (42.1%) | 22 (57.9%) | 1.000 |
| T4 | 24 (42.1%) | 33 (57.9%) | |
| TNM staging | |||
| Stage I | 0 (0%) | 4 (100%) | 0.072 |
| Stage II | 7 (31.8%) | 15 (68.2%) | |
| Stage III | 26 (47.3%) | 29 (52.7%) | |
| Stage IV | 7 (50.0%) | 7 (50.0%) | |
| Degree of differentiation | |||
| Moderately/moderately-poorly differentiated | 16 (38.1%) | 26 (61.9%) | 0.481 |
| Poorly differentiated | 24 (45.3%) | 29 (54.7%) | |
| Pathological types | |||
| Adenocarcinoma | 27 (40.3%) | 40 (59.7%) | 0.581 |
| Signet-ring cell carcinoma/myxoadenocarcinoma | 13 (46.4%) | 15 (53.6%) | |
| Lymphatic or vascular invasion | |||
| Positive | 28 (46.7%) | 32 (53.3%) | 0.238 |
| Negative | 12 (34.3%) | 23 (65.7%) | |
| Nerve invasion | |||
| Positive | 26 (45.6%) | 31 (54.4%) | 0.396 |
| Negative | 14 (36.8%) | 24 (63.2%) | |
| Age(years) | |||
| ≥ 60 | 16 (42.1%) | 22 (57.9%) | 1.000 |
| < 60 | 24 (42.1%) | 33 (57.9%) | |
| Gender | |||
| Male | 24 (35.8%) | 43 (64.2%) | 0.055 |
| Female | 16 (57.1%) | 12 (42.9%) | |